These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 39508845)

  • 21. [MHC class II restricted antigen presentation].
    Hirata S; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():299-303. PubMed ID: 15861672
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human mast cells present antigen to autologous CD4
    Lotfi-Emran S; Ward BR; Le QT; Pozez AL; Manjili MH; Woodfolk JA; Schwartz LB
    J Allergy Clin Immunol; 2018 Jan; 141(1):311-321.e10. PubMed ID: 28624612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
    Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
    Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB; Brett S; Lechler RI
    Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antigen identification for HLA class I- and HLA class II-restricted T cell receptors using cytokine-capturing antigen-presenting cells.
    Lee MN; Meyerson M
    Sci Immunol; 2021 Jan; 6(55):. PubMed ID: 33483338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
    Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
    Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysfunction of antigen processing and presentation by dendritic cells in cancer.
    Bandola-Simon J; Roche PA
    Mol Immunol; 2019 Sep; 113():31-37. PubMed ID: 29628265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
    Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
    Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection.
    Mwangi W; Brown WC; Splitter GA; Zhuang Y; Kegerreis K; Palmer GH
    J Leukoc Biol; 2005 Aug; 78(2):401-11. PubMed ID: 15857936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
    Jäger E; Jäger D; Karbach J; Chen YT; Ritter G; Nagata Y; Gnjatic S; Stockert E; Arand M; Old LJ; Knuth A
    J Exp Med; 2000 Feb; 191(4):625-30. PubMed ID: 10684854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4
    Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
    Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
    Bodey B; Bodey B; Kaiser HE
    In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo.
    Armstrong TD; Clements VK; Ostrand-Rosenberg S
    J Immunother; 1998 May; 21(3):218-24. PubMed ID: 9610914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.
    Van Nuffel AM; Benteyn D; Wilgenhof S; Pierret L; Corthals J; Heirman C; van der Bruggen P; Coulie PG; Neyns B; Thielemans K; Bonehill A
    Mol Ther; 2012 May; 20(5):1063-74. PubMed ID: 22371843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro.
    Brady MS; Lee F; Petrie H; Eckels DD; Lee JS
    Cancer Immunol Immunother; 2000 Feb; 48(11):621-6. PubMed ID: 10663609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.